Study to Evaluate the Drug Interaction Between Dolutegravir (DTG) and Daclatasvir (DCV) in Healthy Adult Subjects
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
This study is designed to estimate the two-way drug interaction between DCV and DTG as a drug
interaction between DTG and DCV is expected to be low and this study is to be performed as
confirmation. This will be a single-center, open-label, three-period, crossover study in
healthy adult subjects. This study to describe and compare steady-state plasma DTG and DCV
pharmacokinetics following administration of DTG 50 mg q24h with and without DCV 60 mg q24h
and following administration of DCV 60 mg q24h with and without DTG 50 mg q24h also the
safety and tolerability was assessed after a repeat dose DTG 50 mg q24h with or without DCV
60 mg q24h and after a repeat dose DCV 60 mg q24h with and without DTG 50 mg q24h